ClinicalTrials.gg

Program

JY231

A development code. Also written as “JY231 Injection” and “JY231 (JY231 injection)”.

Its studies are mostly in Autoimmune Diseases · Burkitt Lymphoma, led by 2 companies.

Furthest: no phase, since Nov 5, 20243 company-led studies, 3 open or runningNext primary completion: Dec 31, 2026

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shenzhen Genocury Biotech22 open or runningno phasesince Nov 5, 2024Nov 5, 2024Dec 2027NCT06890065
LiangZou11 open or runningno phasesince Jul 1, 2025Jul 1, 2025Dec 31, 2026NCT07059169

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 5, 2024First study: no phase study in B-NHLNew to Shenzhen Genocury BiotechShenzhen Genocury Biotech · NCT06678282 · 20 planned · China
  2. Mar 16, 2025No phase study in Burkitt LymphomaShenzhen Genocury Biotech · NCT06890065 · 20 planned · China
  3. Jul 1, 2025LiangZou's first study: no phase study in Autoimmune DiseasesNew to LiangZouLiangZou · NCT07059169 · 20 planned · China

Ahead

  1. Dec 31, 2026Primary completion: no phase study in Autoimmune DiseasesLiangZou · NCT07059169
  2. Dec 2027Primary completion: no phase study in Burkitt LymphomaShenzhen Genocury Biotech · NCT06890065

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07059169Autoimmune Diseases · China–RecruitingLiangZouDec 31, 202620
NCT06890065Burkitt Lymphoma · China–RecruitingShenzhen Genocury BiotechDec 202720
NCT06678282B-NHL · China–RecruitingShenzhen Genocury BiotechSep 30, 202620

How it is read

Names in the registry

  • “JY231 Injection”, 2 entries
  • “JY231 (JY231 injection)”, 1 entry

Codes read as this program: JY231.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.